Aytu BioPharma Inc (AYTU)
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics in the United States and select international markets. The company’s prescription portfolio includes products for attention deficit hyperactivity disorder, such as Adzenys XR-ODT, Cotempla XR-ODT, and Metadate CD. It also markets pediatric products including Karbinal ER, an extended-release carbinoxamine suspension for allergic conditions, along with Poly-Vi-Flor and Tri-Vi-Flor, fluoride-based multivitamin products for infants and children. Headquartered in Denver, Colorado, the company was previously known as Aytu BioScience, Inc. and adopted its current name in March 2021. The listed security is common stock on NASDAQ under the symbol AYTU.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AYTU
|
$2.32
|
7.0% Upside
|
Fair
|
$9.50
|
337.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 29, 2026
|
-0.7x
|
0.7x
|
0.4x
|
23.184 M
|
19.514 M
|
49.7%
|
71.1%
|
-6.2
|
—
|
-4.8%
|
